Market Place
Sourcing Support
Arch Biopartners Doses First Patient in LSALT Phase II Trial
13 Nov 2024 //
PHARMABIZ
Arch Doses First Patient in Canada for LSALT Peptide Trial in AKI
11 Nov 2024 //
GLOBENEWSWIRE
Arch Biopartners Arranges Non-Brokered Private Placement
15 Oct 2024 //
GLOBENEWSWIRE
Closes Units for Debt Settlement
03 Oct 2024 //
GLOBENEWSWIRE
Units for Debt Settlement
26 Sep 2024 //
GLOBENEWSWIRE
Arch Biopartners Gets Approval For LSALT Peptide Phase II Trial In CS-AKI
11 Sep 2024 //
GLOBENEWSWIRE
Arch Biopartners` Cilastatin To Join PONTIAC Phase II Kidney Injury Trial
02 Aug 2024 //
GLOBENEWSWIRE
Arch Biopartners Closes Non-Brokered Private Placement
30 Jul 2024 //
GLOBENEWSWIRE
Arch Biopartners Arranges Non-Brokered Private Placement
29 Jul 2024 //
GLOBENEWSWIRE
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
27 Jun 2024 //
GLOBENEWSWIRE
Arch Biopartners Announces Phase II Trial Approval For LSALT Peptide In CS-AKI
18 Jun 2024 //
GLOBENEWSWIRE
St. Michael`s Hospital Joins LSALT Peptide Phase II Cardiac Surgery AKI Trial
16 Apr 2024 //
GLOBENEWSWIRE
UHN Joins the Ph II Trial of LSALT Pept-Targeting Cardiac Surgery Associated AKI
03 Apr 2024 //
GLOBENEWSWIRE
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT
02 Apr 2024 //
GLOBENEWSWIRE
Arch Biopartners Team Publishes Data from Phase II Trial for LSALT Peptide
18 Mar 2024 //
GLOBENEWSWIRE
University of Calgary Joins the Ph II of LSALT Peptide Targeting Kidney Injury
15 Mar 2024 //
GLOBENEWSWIRE
Arch Bio Announces Dosing of First Patient in Phase II Trial for LSALT Peptide
07 Mar 2024 //
GLOBENEWSWIRE
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin
27 Feb 2024 //
GLOBENEWSWIRE
Arch Receives Health Canada Approval to Conduct PII Trial for LSALT Peptide
10 Jan 2024 //
GLOBENEWSWIRE
Arch Biop Receives Approval to Proceed with Phase II Trial for LSALT Peptide
03 Jan 2024 //
GLOBENEWSWIRE
Arch Biopartners Receives Approval to Proceed with Phase II Kidney Injury Trial
21 Dec 2023 //
GLOBENEWSWIRE
Grant of Options to Directors and Officers
18 Dec 2023 //
GLOBENEWSWIRE
Arch Bio Submits Application to Conduct the Phase II Trial for LSALT Peptide
13 Dec 2023 //
GLOBENEWSWIRE
Shares for Interest Debt Settlement
24 Oct 2023 //
GLOBENEWSWIRE
Arch Bio Submits Application to Conduct a Phase II Trial for LSALT Peptide
22 Sep 2023 //
GLOBENEWSWIRE
Arch Biopartners Engages Independent Trading Group as Market Maker
31 Jul 2023 //
GLOBENEWSWIRE
Arch Biopartners Receives Permission From U.S. FDA to Proceed Phase II AKI Trial
27 Jun 2023 //
GLOBENEWSWIRE
Arch Biopartners Announces +VE Results ofDose Escalation Trial for LSALT Peptide
18 Apr 2023 //
GLOBENEWSWIRE
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
23 Mar 2023 //
GLOBENEWSWIRE
Shares for Interest Debt Settlement; Grants Options
15 Dec 2022 //
GLOBENEWSWIRE
Arch Biopartners Adds Farris Smith as a Strategic Advisor
05 Oct 2022 //
GLOBENEWSWIRE
Arch Biopartners Appoints David Luke as Strategic Advisor
05 Aug 2022 //
CONTRACTPHARMA
Health Canada approves amendment to Arch Biopartners’ Covid-19 trial
16 Feb 2022 //
CLINICALTRIALSARENA
Shares for Interest Debt Settlement
08 Feb 2022 //
GLOBENEWSWIRE
Arch Biopartners Files New Patent Application for Novel Antibody Candidates
10 Jun 2021 //
GLOBENEWSWIRE
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma
15 Apr 2021 //
GLOBENEWSWIRE
Arch Biopartners Enters Exclusive License Agreement with the University
24 Mar 2021 //
PRESS RELEASE
Arch Biopartners secures approval to amend LSALT Peptide trial protocols
17 Mar 2021 //
CLINICALTRIALSARENA
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide
26 Feb 2021 //
FINANCIAL POST
Arch Biopartners Receives Ethics Committee Approval in Turkey PhII Trial
02 Feb 2021 //
GLOBENEWSWIRE
Arch Biopartners Closes Non-Brokered Private Placement
29 Dec 2020 //
GLOBENEWSWIRE
Arch Biopartners Receives Approval from Turkish Ministry of Health PhII Trial
07 Oct 2020 //
GLOBENEWSWIRE
Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide
04 Aug 2020 //
PRESS RELEASE
Cleave Announces Commencement of a Phase 1 Clinical Study of CB-5339
28 Jul 2020 //
BUSINESSWIRE
Broward Health Medical Center Becomes First Clinical Site in U.S. for PhII Trial
28 Jul 2020 //
GLOBENEWSWIRE
Arch Biopartners Engages Global CRO to Conduct LSALTpeptide Metablok PhII trial
14 Jul 2020 //
GLOBENEWLSWIRE
FDA Grants Arch Biopartners Permission to Proceed with Ph II trial LSALT peptide
16 Jun 2020 //
GLOBENEWSWIRE
Arch Biopartners Submits INDA to the FDA for Metablok (LSALT peptide)
08 Jun 2020 //
GLOBENEWSWIRE
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial
19 May 2020 //
GLOBENEWSWIRE
Arch Biopartners Receives Health Canada Approval to COVID-19 PhII Human Trial
08 May 2020 //
GLOBENEWSWIRE
Arch Biopartners Submits Application to Health Canada to COVID19 PhaII Trial
23 Apr 2020 //
GLOBENEWSWIRE
Arch Biopartners Submits Application to Health Canada to Conduct COVID19 PhII
23 Apr 2020 //
BUSINESSINSIDER
Arch Biopartners Expands Dosing in PhI Trial for Metablok to Increase Dose Range
04 Mar 2020 //
GLOBENEWSWIRE
